10X Genomics Inc stock hits 52-week high at 82.76 USD

10X Genomics Inc stock soared to a 52-week high of 82.76 USD, signaling substantial growth for the biotechnology firm. Trading at $82.84, the company's market value now stands at $10.73 billion, reflecting a remarkable surge of 588.62% over the past year. Analysts note the stock's proximity to its 52-week high and its overvaluation compared to its Fair Value, placing it among a select group of companies on the Most Overvalued list.

Investors can access additional insights through 13 InvestingPro Tips, highlighting the company's promising valuation and growth potential. This stock price milestone underscores 10X Genomics' strong performance and market optimism regarding its cutting-edge technologies. As the company expands its product offerings and market presence, investors are keenly observing its trajectory in the competitive biotechnology sector.

In related news, 10X Genomics reported robust second-quarter 2026 earnings, surpassing analyst expectations. The company reported $151.04 million in revenue, outpacing the projected $146.64 million, and posted an adjusted loss per share of $0.14, a significant improvement from the expected $0.24 loss. Despite this positive performance, investors expressed caution due to a softer near-term outlook and the company's transition to the new Atera platform.

Analysts maintain a range of ratings, with Stifel maintaining a Buy rating, citing the upcoming Atera instrument and advancements in spatial biology software as growth drivers. RBC Capital initiated coverage with a Sector Perform rating, balancing the Atera launch with the mature single-cell franchise. Canaccord also raised its price target to $60, maintaining a Buy rating and highlighting potential growth in AI and biopharma sectors.

These developments illustrate the ongoing interest and diverse perspectives on 10X Genomics' future prospects.